Crystal structure of the catalytic domain of protein-tyrosine phosphatase SHP-1
about
Human 70-kDa SHP-1L differs from 68-kDa SHP-1 in its C-terminal structure and catalytic activityCrystal structure of the PTPL1/FAP-1 human tyrosine phosphatase mutated in colorectal cancer: evidence for a second phosphotyrosine substrate recognition pocketDimerization of receptor protein-tyrosine phosphatase alpha in living cellsStructural basis for substrate specificity of protein-tyrosine phosphatase SHP-1Structure-based design of a low molecular weight, nonphosphorus, nonpeptide, and highly selective inhibitor of protein-tyrosine phosphatase 1BCrystal structure of human protein-tyrosine phosphatase SHP-1Crystal structure of human protein tyrosine phosphatase SHP-1 in the open conformationInvestigation of Catalytic Loop Structure, Dynamics, and Function Relationship of Yersinia Protein Tyrosine Phosphatase by Temperature-Jump Relaxation Spectroscopy and X-ray Structural DeterminationSHP family protein tyrosine phosphatases adopt canonical active-site conformations in the apo and phosphate-bound statesCharacterization of the Net1 cell cycle-dependent regulator of the Cdc14 phosphatase from budding yeast.Overview of protein structural and functional folds.Overview of protein folds in the immune system.Tyr66 acts as a conformational switch in the closed-to-open transition of the SHP-2 N-SH2-domain phosphotyrosine-peptide binding cleft.Inhibitors of Src homology-2 domain containing protein tyrosine phosphatase-2 (Shp2) based on oxindole scaffolds.Angiotensin-II-induced apoptosis requires regulation of nucleolin and Bcl-xL by SHP-2 in primary lung endothelial cells.Alteration of SHP-1/p-STAT3 Signaling: A Potential Target for Anticancer Therapy.Structural and evolutionary relationships among protein tyrosine phosphatase domainsProtein tyrosine phosphatases are regulated by mononuclear iron dicitrate.SHP-1 is a target of regorafenib in colorectal cancer.Molecular underpinning of B-cell anergy.Downregulation of signal transducer and activator of transcription 3 by sorafenib: a novel mechanism for hepatocellular carcinoma therapy.Targeting protein tyrosine phosphatases for anticancer drug discovery.Spontaneous insertion of a b2 element in the ptpn6 gene drives a systemic autoinflammatory disease in mice resembling neutrophilic dermatosis in humansAlteration in the gene encoding protein tyrosine phosphatase nonreceptor type 6 (PTPN6/SHP1) may contribute to neutrophilic dermatoses.Rational design of allosteric-inhibition sites in classical protein tyrosine phosphatases.Disrupting VEGF-A paracrine and autocrine loops by targeting SHP-1 suppresses triple negative breast cancer metastasis.Identification of small molecular weight inhibitors of Src homology 2 domain-containing tyrosine phosphatase 2 (SHP-2) via in silico database screening combined with experimental assay.Knowledge-based characterization of similarity relationships in the human protein-tyrosine phosphatase family for rational inhibitor designNovel sorafenib analogues induce apoptosis through SHP-1 dependent STAT3 inactivation in human breast cancer cells.Role of protein tyrosine phosphatases in the modulation of insulin signaling and their implication in the pathogenesis of obesity-linked insulin resistance.Targeting protein tyrosine phosphatase SHP2 for therapeutic intervention.Species-specific color-pattern modifications of butterfly wings.Discovery of novel Src homology region 2 domain-containing phosphatase 1 agonists from sorafenib for the treatment of hepatocellular carcinoma.Astaxanthin treatment reduced oxidative induced pro-inflammatory cytokines secretion in U937: SHP-1 as a novel biological target.Dephosphorylation of the adaptor LAT and phospholipase C-γ by SHP-1 inhibits natural killer cell cytotoxicity.Development of an efficient "substrate-trapping" mutant of Src homology phosphotyrosine phosphatase 2 and identification of the epidermal growth factor receptor, Gab1, and three other proteins as target substrates.Identification of p130cas as an in vivo substrate of receptor protein-tyrosine phosphatase alpha.Sorafenib analogue SC-60 induces apoptosis through the SHP-1/STAT3 pathway and enhances docetaxel cytotoxicity in triple-negative breast cancer cells.Residue 182 influences the second step of protein-tyrosine phosphatase-mediated catalysis.The tyrosine kinase inhibitor nintedanib activates SHP-1 and induces apoptosis in triple-negative breast cancer cells.
P2860
Q22010565-4547BFBC-B5FE-4B07-988C-5AB38D5F1039Q24324478-5F6599D2-021A-4E3D-9E0E-C9A0CFF93741Q24799594-53B2BEC0-2687-462B-9EE5-05FA50709A40Q27621235-A3254E9D-9B22-4B35-9D11-0B38966B29F7Q27622003-69A29BA6-3A5D-473D-8670-B3CC90EF87A4Q27640158-A782D4C2-5B82-47EC-8679-9B44297B9CF3Q27667430-097CD4E0-EAF3-4521-86FF-7283161883D8Q27678944-2B7D2F16-3237-4A54-903F-4E1F088B89EFQ27684212-A5A5AF78-9397-4B78-95AE-C777CD895D32Q27931795-9DBB1AA8-8512-4529-9EE3-727E41945D47Q30368988-6C490E95-0C93-494E-B9C1-B381D72A17EAQ30369011-EA914ECA-0A48-4694-AD62-523AD64EA869Q33279689-4F97C7DA-61A7-47EA-8578-2A13A6A02E87Q33357659-CF65BE5E-ECB1-46EF-A8B5-66AD78A96DAAQ33830299-97F2437B-7F0C-4B07-8A87-CAF093AA0F57Q33838824-D0069A61-A51B-4E83-82DF-6551F5FEC5AAQ34012560-55239F40-C95A-4E0A-8148-158EF8EA7DD7Q34042608-00E7A240-58FF-4A5B-960D-31FC88B668D6Q34227671-C800C7C3-2116-47C0-952B-292EEE4F2D20Q34262298-2BACB4C2-BE0E-4C96-ABC1-3ABA212EEAD9Q34467228-DB99541E-6304-40FD-8F57-F04FF8DC26A4Q34789961-BFEF7270-0DCB-4C06-8C4A-4C8936A2C160Q34805360-DB792352-7DD5-4FAF-8EE3-F57CCB394E3FQ34805483-7145DD90-C5E2-4CCF-9AC5-C56F77E4E985Q35671598-BF549CE8-C951-4754-9860-55660C629324Q37057268-65B3E978-9F40-45EE-95AB-D6AFDD185D9CQ37104928-D271BC68-BE77-4646-998D-1C8AAC75505FQ37610132-A96F9C24-985C-40AC-92E7-C7BF7229717EQ37690338-EA19CBE6-D870-41D4-B6BD-EC68F68E806FQ38165106-97E4A084-24BE-4956-B5CD-00EE09DC44BEQ38261370-CDFB50F3-2CB9-4A38-8A46-44E6011888DCQ38479707-C183C1EB-BA9C-4FA9-B02C-BAE3A01369D4Q39116687-628C0676-1DB8-43F2-AD49-F41C1A6546A1Q39332621-0E619DD1-3567-4468-94C1-5496EB0F85DAQ39738774-6DC9AC7A-431A-434A-87F5-ABE9838D8920Q40605597-45B2A707-B29E-4EF6-A786-A26DFA64B329Q40883240-D8B3EBDD-535E-49A8-9AF7-F4A745E3235BQ41127816-C396E7EA-EA09-4824-BCCF-72D19FBAC64BQ41465181-67DEC3F4-7A0E-4BB3-AC69-97543FBA6054Q41583233-423295FC-4D0E-4459-B4FF-B90BD234062F
P2860
Crystal structure of the catalytic domain of protein-tyrosine phosphatase SHP-1
description
1998 nî lūn-bûn
@nan
1998 թուականի Հոկտեմբերին հրատարակուած գիտական յօդուած
@hyw
1998 թվականի հոտեմբերին հրատարակված գիտական հոդված
@hy
1998年の論文
@ja
1998年論文
@yue
1998年論文
@zh-hant
1998年論文
@zh-hk
1998年論文
@zh-mo
1998年論文
@zh-tw
1998年论文
@wuu
name
Crystal structure of the catalytic domain of protein-tyrosine phosphatase SHP-1
@ast
Crystal structure of the catalytic domain of protein-tyrosine phosphatase SHP-1
@en
Crystal structure of the catalytic domain of protein-tyrosine phosphatase SHP-1
@nl
type
label
Crystal structure of the catalytic domain of protein-tyrosine phosphatase SHP-1
@ast
Crystal structure of the catalytic domain of protein-tyrosine phosphatase SHP-1
@en
Crystal structure of the catalytic domain of protein-tyrosine phosphatase SHP-1
@nl
prefLabel
Crystal structure of the catalytic domain of protein-tyrosine phosphatase SHP-1
@ast
Crystal structure of the catalytic domain of protein-tyrosine phosphatase SHP-1
@en
Crystal structure of the catalytic domain of protein-tyrosine phosphatase SHP-1
@nl
P2093
P2860
P3181
P356
P1476
Crystal structure of the catalytic domain of protein-tyrosine phosphatase SHP-1
@en
P2093
P2860
P304
P3181
P356
10.1074/JBC.273.43.28199
P407
P577
1998-10-23T00:00:00Z